Takeda's pleural mesothelioma agent moves ahead
This article was originally published in Scrip
Executive Summary
Takeda's oncology portfolio has taken a step forward with the start of Phase II trials for the cell cycle disrupting agent CBP501 in malignant pleural mesothelioma.